|Bid||690,000.00 x 0|
|Ask||691,000.00 x 0|
|Day's range||685,000.00 - 696,000.00|
|52-week range||305,000.00 - 863,000.00|
|Beta (5Y monthly)||0.83|
|PE ratio (TTM)||N/A|
|Earnings date||21-Oct-2020 - 26-Oct-2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||499,500.00|
Vir Biotechnology, Inc. (VIR) today announced that is has finalized a process development and manufacturing agreement with Biogen Inc. (BIIB) based on the letter of intent that the companies announced in March. Under the agreement Biogen will perform process development activities and specified manufacturing and process transfer services to enable commercial supply of Vir’s SARS-CoV-2 monoclonal antibodies.
South Korean contract drugs manufacturer Samsung Biologics Co Ltd said on Friday it had signed a deal worth more than $231 million with GlaxoSmithKline PLC (GSK) to supply biopharmaceutical products over the next eight years. The biotech arm of Samsung Group will start with manufacturing drugs for autoimmune disease lupus for GSK with the aim to expand to making other drugs for the British drugmaker, an official at Samsung Biologics told Reuters. "Samsung Biologics entered the biopharma industry with the goal to help our clients bring valuable biological medicines to patients faster," CEO Kim Tae-han said in a statement.
SAN FRANCISCO, May 12, 2020 -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today.